MGC Pharma expands presence in budding UK cannabis market

0
349

Specialist pot-stock, MGC Pharmaceuticals (ASX:MXC), revealed this morning that luxury British department store, Harvey Nichols, has expanded the sale of the premium cannabidiol (CBD) MGC Derma and Derma Plus collections to two further stores within the UK — Birmingham and Edinburgh. This expansion comes from strong and increasing demand following the overwhelming success of the launch at the Knightsbridge store in the June 2018 quarter. Revenue is expected to increase with these additional two stores, with sales driven further by a razor-sharp PR and marketing campaign that has positively impacted the MGC Derma footprint within the UK. Of course, as always, success is not guaranteed — consider your own personal circumstances before investing, and seek professional financial advice. The ongoing campaign, which has targeted press and social influencers, has enabled considerable brand exposure for MGC Derma across a range of prestigious (and far-reaching) print and online publications. These include The Guardian, which has a circulation of 7. MGC Pharma expands presence in budding UK cannabis market

thumbnail courtesy of finfeed.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here